Format

Send to

Choose Destination
Ann Oncol. 2015 Dec;26(12):2375-91. doi: 10.1093/annonc/mdv383. Epub 2015 Sep 14.

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

Author information

1
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore jarushka_14@yahoo.com.
2
Providence Portland Medical Center and Earl A. Chiles Research Institute, Portland.
3
Department of Medicine and Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, USA.
4
Department of Dermatology, Medical University of Vienna, Vienna, Austria.
5
Dermatology Service, Memorial Sloan Kettering Cancer Center, New York Department of Medicine, Weill Cornell Medical College, New York, USA.
6
Department of Medicine and Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, USA Department of Medicine, Weill Cornell Medical College, New York, USA.

Abstract

Immune checkpoint antibodies that augment the programmed cell death protein 1 (PD-1)/PD-L1 pathway have demonstrated antitumor activity across multiple malignancies, and gained recent regulatory approval as single-agent therapy for the treatment of metastatic malignant melanoma and nonsmall-cell lung cancer. Knowledge of toxicities associated with PD-1/PD-L1 blockade, as well as effective management algorithms for these toxicities, is pivotal in order to optimize clinical efficacy and safety. In this article, we review selected published and presented clinical studies investigating single-agent anti-PD-1/PD-L1 therapy and trials of combination approaches with other standard anticancer therapies, in multiple tumor types. We summarize the key adverse events reported in these studies and their management algorithms.

KEYWORDS:

adverse event; anti-PD-1; anti-PD-L1; immune checkpoint antibody; toxicity

PMID:
26371282
PMCID:
PMC6267867
DOI:
10.1093/annonc/mdv383
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center